Last reviewed · How we verify
NCT03869476: BioScoreSMP
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
NA trial testing Non-invasive diagnosis score in Myeloproliferative Disorder in 133 participants. Completed in 30 January 2024.
30 January 2024
Quick facts
| Lead sponsor | University Hospital, Angers |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 133 |
| Start date | 30 July 2019 |
| Primary completion | 30 January 2024 |
| Estimated completion | 30 January 2024 |
| Sites | 2 locations across France |
Drugs / interventions tested
- Non-invasive diagnosis score
Conditions studied
- Myeloproliferative Disorder — all drugs for Myeloproliferative Disorder →
- Essential Thrombocythemia — all drugs for Essential Thrombocythemia →
- Primary Myelofibrosis, Prefibrotic Stage — all drugs for Primary Myelofibrosis, Prefibrotic Stage →
- Primary Myelofibrosis, Fibrotic Stage — all drugs for Primary Myelofibrosis, Fibrotic Stage →
Sponsor
University Hospital, Angers
Who can join
Adults 18 to 99, any sex, with Myeloproliferative Disorder or Essential Thrombocythemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03869476
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloproliferative Disorder
Currently open trials in the same condition.
- NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
- NCT05884333 — Cord Blood Transplant in Adults With Blood Cancers · Phase 2 · recruiting
- NCT03852407 — Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten · Phase 2 · recruiting
- NCT03480360 — Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression · Phase 3 · active not recruiting
Other University Hospital, Angers trials
Trials by the same sponsor.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07470294 — Effectiveness of Different Surgical Techniques for Curative Treatment of Pilonidal Sinus Disease in the Pediatric Popula · not yet recruiting
- NCT07409597 — Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease · NA · not yet recruiting
- NCT07468565 — Surgical Approach for the Treatment of Hirschsprung Disease Using the Swenson Technique (SMILES) · not yet recruiting
- NCT07452952 — Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distre · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03869476 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Angers
- Last refreshed: 30 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03869476.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing